ENANTA PHARMACEUTICALS INC
Company Stats
- Market Cap
- $383.9M
- as of Sep 30, 2026
- Shares Outstanding
- 29.1M
- Free Float
- 76.1%
Income Statement
- Revenue
- $65.3M
- Operating Income
- -$85.3M
- Net Income
- -$81.9M
- EBITDA
- -$80.8M
- Revenue Growth, 3Y
- -8.8%
- FCF Margin, 3Y Avg
- -111.3%
- FCF Margin, Worst Year
- -143.0%
Cash Flow
- Free Cash Flow
- -$32.2M
- FCF Yield
- -8.4%
- Owner FCF Yield
- -13.2%
Balance Sheet
- Cash & Equivalents
- $32.3M
Returns & Capital
- SBC, 3Y Avg
- $24.5M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | $65.3M | -$32.2M | -49.2% |
| FY2024 | $67.6M | -$96.7M | -143.0% |
| FY2023 | $79.2M | -$112.2M | -141.7% |
| FY2022 | $86.2M | -$86.9M | -100.9% |
| FY2021 | $97.1M | -$70.7M | -72.9% |
Annual filing data through FY ended September 30, 2025; shares and float as of October 10, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Stronger demand supports expansion as pricing diverges
Healthcare Earnings: Demand Surges, Costs Bite Back